Piramal Pharma Achieves 1,500th ADC Batch Milestone, Reinforcing Leadership in Oncology Manufacturing

Piramal Pharma Achieves Milestone in Antibody-Drug Conjugate Manufacturing

Piramal Pharma Solutions has attained a significant milestone with the completion of its 1,500th antibody-drug conjugate (ADC) batch at its Grangemouth facility in the UK. This achievement, announced on March 16, 2026, underscores Piramal's position as a leading Contract Development and Manufacturing Organization (CDMO) specializing in bioconjugate therapies for oncology patients. With over two decades of experience and being the first FDA-approved ADC CDMO, Piramal sets a benchmark in the ADC landscape, showcasing its ability to produce biotherapeutics that are essential for improving patient outcomes.

The Grangemouth facility plays a critical role in Piramal's ADCelerate™ program, which streamlines the transition from R&D to Good Manufacturing Practice (GMP) production. This program facilitates efficient technology transfers backed by robust project management and quality assurance teams. By leveraging integrated solutions that encompass everything from proof-of-concept studies to large-scale commercial production, Piramal maintains its commitment to delivering innovative therapies. The facility's recent accomplishment of producing 1,500 ADC batches—including clinical, commercial, and non-GMP products—illustrates its capacity to handle diverse manufacturing needs backed by a solid regulatory record.

Piramal's extensive portfolio of produced bioconjugates represents a combination of experience and pioneering technology that has positioned the company as a leader in the market. The expertise of the Science Collective enhances project outcomes through strategic guidance and technical insight, securing high-quality manufacturing practices that comply with industry standards. With this recent milestone, Piramal reaffirms its dedication to delivering impactful biotherapeutics, ensuring that patients have access to the vital therapies they need.

In other relevant industry developments, Whitehawk Therapeutics, a clinical-stage oncology therapeutics company, announces its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting from April 17-22, 2026. The company intends to present three preclinical abstracts on its next-generation ADC portfolio, which focuses on optimized designs aimed at improving cancer patient outcomes, featuring promising therapeutic indices.

These presentations showcase innovative bioconjugation processes and advanced linker-payload technologies that could significantly impact the ADC industry, emphasizing the ongoing commitment of companies like Whitehawk to advance cancer therapies through rigorous research and development. While Piramal leads in manufacturing capabilities, complementary innovations in ADC design continue to shape the future of targeted cancer treatments.